Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 2/2002

01-04-2002 | Review Article

Sweet’s Syndrome

A Review of Current Treatment Options

Authors: Dr Philip R. Cohen, Razelle Kurzrock

Published in: American Journal of Clinical Dermatology | Issue 2/2002

Login to get access

Abstract

Sweet’s syndrome was originally described in 1964 by Dr Robert Douglas Sweet as an ‘acute febrile neutrophilic dermatosis’. The syndrome is characterized by pyrexia, elevated neutrophil count, painful red papules, nodules, plaques (which may be recurrent) and an infiltrate consisting predominantly of mature neutrophils that are diffusely distributed in the upper dermis. In addition to skin and mucosal lesions, Sweet’s syndrome can also present with extra-cutaneous manifestations. Sweet’s syndrome can be classified based upon the clinical setting in which it occurs: classical or idiopathic Sweet’s syndrome, malignancy-associated Sweet’s syndrome and drug-induced Sweet’s syndrome.
Systemic corticosteroids have been considered the ‘gold standard’ for the treatment of patients with Sweet’s syndrome; in addition, treatment with topical and/or intralesional corticosteroids may be effective as either monotherapy or adjuvant therapy. However, spontaneous resolution of the symptoms and lesions has occurred in several patients with Sweet’s syndrome for whom disease-specific therapeutic intervention was not initiated and in some of the patients with drug-induced Sweet’s syndrome after withdrawal of the dermatosis-causing medication. Oral therapy with either potassium iodide or colchicine typically results in rapid resolution of Sweet’s syndrome symptoms and lesions; therefore, in patients with Sweet’s syndrome who have a potential systemic infection or in whom corticosteroids are contraindicated, it is reasonable to initiate treatment with these agents as a first-line therapy. Indomethacin, clofazimine, dapsone, and cyclosporine have also been effective therapeutic agents for managing Sweet’s syndrome. However, indomethacin and clofazimine appear less effective than corticosteroids, potassium iodide, and colchicine. Appropriate initial and follow-up laboratory monitoring is necessary when treating with either dapsone or cyclosporine because of the potential for severe adverse drug-associated effects. Systemic antibacterials with activity against Staphylococcus aureus frequently result in partial improvement of Sweet’s syndrome lesions when they are impetiginized or secondarily infected. In some patients with dermatosis-associated bacterial infections, organism-sensitive specific systemic antibacterials have been helpful in the management of their Sweet’s syndrome. Although patients with hematologic malignancy-associated Sweet’s syndrome often receive cytotoxic chemotherapy agents and antimetabolic drugs for the treatment of their underlying disorder, these agents are seldom used solely for the management of the symptoms and lesions of Sweet’s syndrome. The treatment of patients with Sweet’s syndrome with either etretinate or interferon-α have been reported as single case reports; both patients had improvement of not only their Sweet’s syndrome lesions, but also their associated hematologic disorder.
Literature
1.
2.
Cohen P.R., Kurzrock R. Sweet’s syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol 2000; 18: 265–82PubMedCrossRef
3.
4.
Cohen P.R., Almeida L., Kurzrock R. Acute febrile neutrophilic dermatosis. Am Fam Physician 1989; 39 (3): 199–204PubMed
5.
6.
Kemmett D., Hunter J.A.A. Sweet’s syndrome: a clinicopathologic review of twenty-nine cases. J Am Acad Dermatol 1990; 23: 503–7PubMedCrossRef
7.
Sitjas D., Cuatrecasas M., De Moragas J.M. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Int J Dermatol 1993; 32: 261–8PubMedCrossRef
8.
Hommel L., Harms M., Saurat J.H. The incidence of Sweet’s syndrome in Geneva: a retrospective study of 29 cases. Dermatology 1993; 187: 303–5PubMedCrossRef
9.
von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 1994; 31: 535–56PubMedCrossRef
10.
Chan H.-L., Lee Y.-S., Kuo T.-T. Sweet’s syndrome: clinicopathologic study of eleven cases. Int J Dermatol 1994; 33: 425–32PubMedCrossRef
11.
Fett D.L., Gibson L.E., Su W.P.D. Sweet’s syndrome: systemic signs and symptoms and associated disorders. Mayo Clin Proc 1995; 70: 234–40PubMedCrossRef
12.
Cohen P.R., Kurzrock R. Diagnosing the Sweet syndrome. Ann Intern Med 1989; 110: 573–4PubMed
13.
Honigsmann H., Cohen P.R., Wolff K. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). In: Freedberg I.M., Eisen A.Z., Wolff K., et al., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill Health Professions Division, 1999: 1117–23
14.
Cohen P.R. Paraneoplastic dermatopathology: cutaneous paraneoplastic syndromes. Adv Dermatol 1996; 11: 215–52PubMed
15.
Cohen P.R., Kurzrock R. Extracutaneous manifestations of Sweet’s syndrome: steroid-responsive culture-negative pulmonary lesions letter]. Am Rev Respir Dis 1992; 146: 269PubMed
16.
Cohen P.R., Kurzrock R. The pathogenesis of Sweet’s syndrome letter]. J Am Acad Dermatol 1991; 25: 734PubMedCrossRef
17.
Cohen P.R. Pregnancy-associated Sweet’s syndrome: world literature review. Obstet Gynecol Survey 1993; 48: 584–7CrossRef
18.
Cohen P.R., Talpaz M., Kurzrock R. Malignancy-associated Sweet’s syndrome: review of the world literature. J Clin Oncol 1988; 6: 1887–97PubMed
19.
Cohen P.R. Cutaneous paraneoplastic syndromes. Am Fam Physician 1994; 50: 1273–82PubMed
20.
Kurzrock R., Cohen P.R. Cutaneous paraneoplastic syndromes in solid tumors. Am J Med 1995; 99: 662–71PubMedCrossRef
21.
Cohen P.R. Cutaneous manifestations of internal malignancy. In: Callen J.P., Bone R.C., editors. Current practice of medicine. Vol. 2. Section V. Philadelphia (PA): Current Medicine, 1996: V: 19.1–19.13
22.
Cohen P.R., Kurzrock R. Paraneoplastic syndromes of the skin. In: Conn R.B., Borer W.Z., Snyder J.W., editors. Current Diagnosis 9. Philadelphia (PA): W.B. Saunders Company, 1997: 1199–1206
23.
Cohen P.R. Cutaneous paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc 1993; 68: 620–1PubMed
24.
Cohen P.R., Kurzrock R. Mucocutaneous paraneoplastic manifestations of hematologic malignancies: the reply. Am J Med 1996; 101: 231–3CrossRef
25.
26.
Walker D.C., Cohen P.R. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet’s syndrome. J Am Acad Dermatol 1996; 34: 918–23PubMedCrossRef
27.
Su W.P.D., Liu H.-N.H. Diagnostic criteria for Sweet’s syndrome. Cutis 1986; 37: 167–74PubMed
28.
Shimizu T., Yoshida I., Eguchi H., et al. Sweet syndrome in a child with aplastic anemia receiving recombinant granulocyte colony-stimulating factor. J Pediatr Hematol Oncol 1996; 18: 282–4PubMedCrossRef
29.
Garty B.Z., Levy I., Nitzan M., et al. Sweet syndrome associated with G-CSF treatment in a child with glycogen storage disease type Ib. Pediatrics 1996; 97: 401–3PubMed
30.
Mensing H., Kowalzick L. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) caused by minocycline. Dermatologica 1991; 182: 43–6PubMedCrossRef
31.
Thibault M.-J., Billick R.C., Srolovitz H. Minocycline-induced Sweet’s syndrome. J Am Acad Dermatol 1992; 27: 801–4PubMedCrossRef
32.
Retief C.R., Malkinson F.D. Nitrofurantoin-associated Sweet’s syndrome. Cutis 1999; 63: 177–9PubMed
33.
Gilmour E., Chalmers R.J.G., Rowlands D.J. Drug-induced Sweet’s syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine. Br J Dermatol 1995; 133: 490–1PubMedCrossRef
34.
Paydas S., Berksoy S., Seyrek E., et al. Sweet’s syndrome associated with G-CSF. Br J Haematol 1993; 85: 191–2PubMedCrossRef
35.
Park J.W., Mehrotra B., Barnett B.O., et al. The Sweet syndrome during therapy with granulocyte-colony stimulating factor. Ann Intern Med 1992; 116: 996–8PubMed
36.
Peters M.S., Argenyi Z., Cerio R., et al. Friday evening slide symposium case 10: neutrophilic dermatosis due to granulocytic colony stimulating factor (G-CSF)]. J Cutan Pathol 1993; 20: 465–78PubMedCrossRef
37.
Morioka N., Otsuka F., Nogita T., et al. Neutrophilic dermatosis with myelodysplastic syndrome: nuclear segmentation anomalies of neutrophils in the skin lesion and in peripheral blood. J Am Acad Dermatol 1990; 23: 247–9PubMedCrossRef
38.
Van Kamp H., Van den Berg E., Timens W., et al. Sweet’s syndrome in myeloid malignancy: a report of two cases. Br J Haematol 1994; 86: 415–7PubMedCrossRef
39.
Asnis L.A., Gaspar A.A. Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 1995; 33: 393–410PubMedCrossRef
40.
Jain K.K. Sweet’s syndrome associated with granulocyte colony-stimulating factor. Cutis 1966; 57: 107–10
41.
Prevost-Blank P.L., Shwayder T.A. Sweet’s syndrome secondary to granulocyte colony-stimulating factor. J Am Acad Dermatol 1996; 35: 995–7PubMedCrossRef
42.
Richard M.A., Grob J.J., Laurans R., et al. Sweet’s syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia. J Am Acad Dermatol 1996; 35: 629–31PubMedCrossRef
43.
Berger T.G., Dhar A., McCalmont T.H. Neutrophilic dermatoses in HIV infection. J Am Acad Dermatol 1994; 31: 1045–7PubMedCrossRef
44.
Fukutoku M., Shimizu S., Ogawa Y., et al. Sweet’s syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anemia. Br J Haematol 1994; 86: 645–8PubMedCrossRef
45.
Petit T., Frances C., Marinho E., et al. Lymphoedema-area-restricted Sweet syndrome during G-CSF treatment letter]. Lancet 1996; 347: 690PubMedCrossRef
46.
Tefany F.J., Georgouras K. A neutrophilic reaction of Sweet’s syndrome type associated with the oral contraceptive. Aust J Dermatol 1991; 32: 55–9CrossRef
47.
Cox N.H., O’Brien H.A.W. Sweet’s syndrome associated with trans-retinoic acid treatment in acute promyelocytic leukemia. Clin Exp Dermatol 1994; 19: 51–2PubMedCrossRef
48.
Piette W.W., Trapp J.F., O’Donnell M.J., et al. Acute neutrophilic dermatosis with myeloblastic infiltrate in a leukemia patient receiving all-trans-retinoic acid therapy. J Am Acad Dermatol 1994; 30: 293–7PubMedCrossRef
49.
Tomas J.F., Escudero A., Fernandez-Ranada J. All-trans retinoic acid treatment and Sweet syndrome letter]. Leukemia 1994; 8: 1596PubMed
50.
Christ E., Linka A., Jacky E., et al. Sweet’s syndrome involving the musculoskeletal system during treatment of promyelocytic leukemia with all-trans retinoic acid. Leukemia 1996; 10: 731–4PubMed
51.
Keefe M., Wakeel R.A., Kerr R.E.I. Sweet’s syndrome, plantar pustulosis, and vulvar pustules. Clin Exp Dermatol 1988; 13: 344–6PubMedCrossRef
52.
Cobb M.W. Furosemide-induced eruption simulating Sweet’s syndrome. J Am Acad Dermatol 1989; 21: 339–43PubMedCrossRef
53.
Ramsey-Goldman R., Franz T., Solano F.X., et al. Hydralazine-induced lupus and Sweet’s syndrome: report and review of the literature. J Rheumatol 1990; 17: 682–4PubMed
54.
Sequiera W., Polinsky R.B., Alrenga D.P. Neutrophilic dermatosis (Sweet’s syndrome): association with a hydralazine-induced lupus syndrome. Am J Med 1986; 81: 558–60CrossRef
55.
Satra K.H., Zalka A., Cohen P.R., et al. Sweet’s syndrome and pregnancy. J Am Acad Dermatol 1994; 30: 297–300PubMedCrossRef
56.
Cohen P.R., Kurzrock R. Chronic myelogenous leukemia and Sweet syndrome. Am J Hematol 1989; 32: 134–7PubMedCrossRef
57.
Cohen P.R. Acral erythema: a clinical review. Cutis 1993; 20: 15–20
58.
59.
Cohen P.R., Holder W.R., Rapini R.P. Concurrent Sweet’s syndrome and erythema nodosum: a report, world literature review and mechanism of pathogenesis. J Rheumatol 1992; 19: 814–20PubMed
60.
Cohen P.R., Holder W.R., Tucker S.B., et al. Sweet syndrome in patients with solid tumors. Cancer 1993; 72: 2723–31PubMedCrossRef
61.
Cohen P.R., Holder W.R. Pentoxifylline for Sweet’s syndrome. J Am Acad Dermatol 1995; 32: 533–4PubMedCrossRef
62.
Cohen P.R., Kurzrock R. Paraneoplastic Sweet’s syndrome. Emerg Med 1994; 26 (2): 37–8
63.
Kurzrock R., Cohen P.R. Mucocutaneous paraneoplastic manifestations of hematologic malignancies. Am J Med 1995; 99: 207–16PubMedCrossRef
64.
Cohen P.R., Kurzrock R. Mucocutaneous paraneoplastic syndromes (Seminars in Oncology). Semin Oncol 1997; 24: 334–59PubMed
65.
Purdy M.J., Fairbrother G.E. Case reports: acute febrile neutrophilic dermatosis of Sweet. Aust J Dermatol 1971; 12: 172–7CrossRef
66.
Moreland L.W., Brick J.E., Kovach R.E., et al. Acute febrile neutrophilic dermatosis (Sweet’s syndrome): a review of the literature with emphasis on musculoskeletal manifestations. Sem Arthr Rheum 1988; 17 (3): 143–55CrossRef
67.
Pouchot J., Bourgeots-Droin C., Vinceneu P., et al. Sweet’s syndrome and mediastinal lymphadenopathy due to sarcoidosis: three cases of a new association. Arch Dermatol 1993; 129: 1062–4PubMedCrossRef
68.
Bourke J.F., Keohane S., Long C.C., et al. Sweet’s syndrome and malignancy in the UK. Br J Dermatol 1997; 137: 609–13PubMedCrossRef
69.
Okamoto H., Kohno A., Tsuru N., et al. Sweet’s syndrome and thyroid cancer. Rincho Dermatol 1988; 30: 1212–3
70.
Akovbyan V., Talanin N., Tukhvatullina Z. Sweet’s syndrome in patients with kidney and liver disorders. Cutis 1992; 49: 448–50PubMed
71.
O’Connor R.C., Garcia I.M.T., Rodriguez D.A., et al. Tonsil cancer and Sweet’s syndrome. Otolaryngol Head Neck Surg 1998; 119: 709–10CrossRef
72.
Baron F., Sybert V.P., Andrews R.G. Cutaneous and extracutaneous neutrophilic infiltrates (Sweet’s syndrome) in three patients with Fanconi anemia. J Pediatr 1989; 115: 726–9PubMedCrossRef
73.
Bello Lopez J.L., Fonseca E., Manso F. Sweet’s syndrome during the chronic phase of chronic myeloid leukemia. Acta Haematol 1990; 84: 207–8CrossRef
74.
Goh C.L., Alora M., Kohar Y. Sweet’s syndrome in a skin clinic in Singapore: an epidemiology study. Ann Acad Med Singapore 1996; 25: 222–7PubMed
75.
van Rooijen M.M., Brand C.U., Braathen L.R. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Dermatology 1998; 197: 299PubMedCrossRef
76.
Harary A.M. Sweet’s syndrome associated with rheumatoid arthritis. Arch Intern Med 1983; 143: 1993–5PubMedCrossRef
77.
Case J.D., Smith S.Z., Callen J.P. The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet’s syndrome. Cutis 1989; 44: 125–9PubMed
78.
Fain O., Mathieu E., Feton N., et al. Intestinal involvement in Sweet’s syndrome. J Am Acad Dermatol 1996; 35: 989–90PubMedCrossRef
79.
Altomare G., Capella G.L., Frigerio E. Sweet’s syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate. Haematologica (Pavia) 1996; 81: 54–8
80.
Myatt A.E., Baker D.J., Byfield D.M. Sweet’s syndrome: a report on the use of potassium iodide. Clin Exp Dermatol 1987; 12: 345–9PubMedCrossRef
81.
Chen T.C., Goldstein D.A., Tessler H.H., et al. Scleritis associated with acute febrile neutrophilic dermatosis (Sweet’s syndrome) letter]. Br J Ophthalmol 1998; 82: 328–9PubMedCrossRef
82.
Fanti P.A., Moise G.M., Vuga S., et al. Sindrome di Sweet in paziente con carcinome a cellule chiare del rene. Chron Derm 1984; 15: 175–9
83.
Nguyen K.Q., Hurst C.G., Pierson D.L., et al. Sweet’s syndrome and ovarian carcinoma. Cutis 1983; 32: 152–4PubMed
84.
Brodkin R.H., Schwartz R.A. Sweet’s syndrome with myelofibrosis and leukemia: partial response to interferon. Dermatology 1995; 190: 160–3PubMedCrossRef
85.
Bennion S.D., Fitzpatrick J.E., DiBella N.J. Sweet’s syndrome in association with breast cancer. Cutis 1987; 82: 1084–5
86.
Woodrow S.L., Munn S.E., Basarab T., et al. Sweet’s syndrome in association with non-Hodgkin’s lymphoma. Clin Exp Dermatol 1996; 21: 357–9PubMedCrossRef
87.
Horio T., Imamura S., Danno K., et al. Treatment of acute febrile neutrophilic dermatosis (Sweet’s syndrome) with potassium iodide. Dermatologica 1980; 160: 341–7PubMedCrossRef
88.
Horio T., Danno K., Okamoto H., et al. Potassium iodide in erythema nodosum and other erythematous dermatoses. J Am Acad Dermatol 1983; 9: 77–81PubMedCrossRef
89.
Bruyn G.A.W., Missier E.T.A., Toonstra J., et al. Sweet’s syndrome. Neth J Med 1990; 36: 62–8PubMed
90.
Kannan R., Dutta T.K., Garg B.B., et al. Sweet’s syndrome in chronic myeloid leukemia letter]. Postgrad Med J 1995; 71: 383PubMedCrossRef
91.
Su W.P.D., Fett D.L., Gibson L.E., et al. Sweet syndrome: acute febrile neutrophilic dermatosis. Seminars Dermatol 1995; 14 (2): 173–8CrossRef
92.
Smith H.R., Ashton R.E., Beer T.W., et al. Neutrophil-poor Sweet’s syndrome with response to potassium iodide letter]. Br J Dermatol 1998; 139: 555–6PubMedCrossRef
93.
Schiff B.L., Kern A.B., Bercovitch L. Sweet’s syndrome: report of two atypical cases. Postgrad Med 1982; 71 (1): 55–60PubMed
94.
Suehisa S., Tagami H. Treatment of acute februle neutrophilic dermatosis (Sweet’s syndrome) with colchicine letter]. Br J Dermatol 1981; 105: 483PubMedCrossRef
95.
Miyachi Y., Niwa Y. Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates. Br J Dermatol 1982; 107: 209–14PubMedCrossRef
96.
Honma K., Saga K., Onodera H., et al. Potassium iodide inhibits neutrophil chemotaxis. Acta Derm Venereol (Stockh) 1990; 70: 247–9
97.
Sanchez M.R. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine. Clin Dermatol 2000; 18: 131–45PubMedCrossRef
98.
99.
Sullivan T.P., King Jr L.E., Boyd A.S. Colchicine in dermatology. J Am Acad Dermatol 1998; 39: 993–9PubMedCrossRef
100.
Suehisa S., Tagami H., Inoue F., et al. Colchicine in the treatment of acute febrile neutrophilic dermatosis (Sweet’s syndrome). Br J Dermatol 1983; 180: 99–101CrossRef
101.
Hoffman G.S. Treatment of Sweet’s syndrome (active febrile neutrophilic dermatosis) with indomethacin. J Rheumatol 1977; 4: 201–6PubMed
102.
Hehlmann R., Ludershmidt C., Goebel F.D., et al. Relapsing acute febrile neutrophilic dermatosis and essential thrombocythemia. Blut 1984; 48: 297–305PubMed
103.
Jeanfils S., Joly P., Young P., et al. Indomethacin treatment of eighteen patients with Sweet’s syndrome. J Am Acad Dermatol 1997; 36: 436–9PubMedCrossRef
104.
Trentham D.E., Masi A.T., Bale G.F. Arthritis with an inflammatory dermatosis resembling Sweet’s syndrome: report of a unique case and review of the literature on arthritis associated with inflammatory dermatoses. Am J Med 1976; 61: 424–32PubMedCrossRef
105.
Callen J.P. Acute febrile neutrophilic dermatosis (Sweet’s syndrome) and the related conditions of ‘bowel bypass: syndrome and bullous pyoderma gangrenosum. Dermatol Clin 1985; 3: 153–63PubMed
106.
Quintana E.C., de Mendarozqueta M.G., Arrazuria M.A.G., et al. Concurrent Sweet’s syndrome and Lofgren’s syndrome. J Rheumatol 1996; 23: 1995–8
107.
Suarez S.M., Cohen P.R., DeLeo V.A. Bullous photosensitivity to naproxen: ‘pseudoporphyria. ’ Arthritis Rheum 1990; 33: 903–8CrossRef
108.
Petrozzi J.W., Warthan T.L. Sweet’s syndrome: unique local response to streptococcal antigen. Cutis 1976; 17: 267–72PubMed
109.
Saxe N., Gordon W. Acute febrile neutrophilic dermatosis (Sweet’s syndrome): four case reports. S Afr Med J 1978; 53: 253–6PubMed
110.
Sharpe G.R., Leggat H.M. A case of Sweet’s syndrome and myelodysplasia: response to cyclosporin. Br J Dermatol 1992; 127: 538–9PubMedCrossRef
111.
von den Driesch P., Steffan C., Zobe A., et al. Sweet’s syndrome: therapy with cyclosporin. Clin Exp Dermatol 1994; 19: 274–7PubMedCrossRef
112.
Wilson D.M., John G.R., Callen J.P. Peripheral ulcerative keratitis: an extracutaneous neutrophilic disorder: report of a patient with rheumatoid arthritis, pustular vasculitis, pyoderma gangrenosum, and Sweet’s syndrome with an excellent response to cyclosporine therapy. J Am Acad Dermatol 1999; 40: 331–4PubMedCrossRef
113.
Soppi E., Nousiainen T., Seppa A., et al. Acute febrile neutrophilic dermatosis in association with myelodysplastic syndromes: a report of three cases and a review of the literature. Br J Haematol 1989; 73: 43–7PubMedCrossRef
114.
Bourke J.F., Berth-Jones J., Graham-Brown R.A.C. Sweet’s syndrome responding to cyclosporin. Br J Dermatol 1992; 127: 36–8PubMedCrossRef
115.
Fitzgerald R.L., McBurney E.I., Nesbitt Jr L.T. Sweet’s syndrome. Int J Dermatol 1996; 35: 9–15PubMedCrossRef
116.
Cather J.C., Abramovits W., Menter A. Cyclosporin and tacrolimus in dermatology. Dermatol Clin 2001; 19: 119–37PubMedCrossRef
117.
Cohen P.R. A therapeutic alternative for managing cyclosporine- and retinoid-induced hypertriglyceridemia letter]. Acta Derm Venereol (Stockh) 1993; 73: 310
118.
Wolf R., Tuzun B., Tuzun Y. Dapsone: unapproved uses or indications. Clin Dermatol 2000; 18: 37–53PubMedCrossRef
119.
120.
Stendhal O., Molin L., Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 1978; 62: 214CrossRef
121.
Aram H. Acute febrile neutrophilic dermatosis (Sweet’s syndrome): response to dapsone. Arch Dermatol 1984; 120: 245–7PubMedCrossRef
122.
El Sherif A.I., Bharija S.C., Belhaj M.S., et al. Dapsone in Sweet syndrome letter]. Int J Dermatol 1990; 29: 737
123.
Delfino M., Suppa F., DeLuca F., et al. Sweet’s syndrome and toxoplasmosis: a coincidental association? Dermatologica 1985; 171: 102–5PubMedCrossRef
124.
Meyerson M.A., Cohen P.R. Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus. Mayo Clin Proc 1994; 69: 1159–62PubMed
125.
Elsner P., Hartmann A.A., Lechner W. Sweet’s syndrome associated with Yersinia enterocolitica infection. Dermatologica 1986; 173: 85–9PubMedCrossRef
126.
Joshi R.K., Atukorala D.N., Abanmi A., et al. Successful treatment of Sweet’s syndrome with doxycycline. Br J Dermatol 1993; 128: 584–6PubMedCrossRef
127.
Escallier F., Gaudard S., Courtois J.M., et al. Syndrome de Sweet et infection a Yersinia enterocolitica French]. Ann Dermatol Venereol (Paris) 1990; 117: 858–60
128.
Amichai B., Lazarov A., Cagnano M., et al. Sweet’s syndrome and chlamydial infection. Aust J Dermatol 1993; 34: 31–3CrossRef
129.
Amichai B., Lazarov A., Halevy S. Sweet’s syndrome letter]. J Am Acad Dermatol 1995; 33: 144–5PubMed
130.
Zillikens D., Goldsstein R.K., Elsner P., et al. Sweet’s syndrome associated with Salmonella typhimurium infection. Acta Derm Venereol (Stockh) 1991; 71: 77–9
131.
Banet D.E., McClave S.A., Callen J.P. Oral metronidazole, an effective treatment for Sweet’s syndrome in a patient with associated inflammatory bowel disease. J Rheumatol 1994; 21: 1766–8PubMed
132.
Spillman D.H., Carabajal M.G., Errecaborde M.S., et al. Acute febrile neutrophilic dermatosis (Sweet’s syndrome). Book of abstracts for the 18th World Congress of Dermatology. Dermatology: progress and perspectives; 1992 Jun 12–18; New York, 147A
133.
Kurkcuoglu N., Aksoy F. Sweet’s syndrome associated with Helicobacter pylori infection. J Am Acad Dermatol 1997; 37: 123–4PubMedCrossRef
134.
Meyerson M.A., Cohen P.R., Hymes S.R. Tongue hyperpigmentation associated with minocycline therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 79: 180–4PubMedCrossRef
135.
Unis M.E., Hill G.S. Sweet’s syndrome associated with acute renal failure. Cutis 1987; 40: 139–42PubMed
136.
Sarkany R.P.E., Burrows N.P., Grant J.W., et al. The pustular eruption of ulcerative colitis: a variant of Sweet’s syndrome letter]. Br J Dermatol 1998; 138: 365–6PubMedCrossRef
137.
Feliu E., Cervantes F., Ferrando J., et al. Neutrophilic pustulosis associated with chronic myeloid leukemia, a special form of Sweet’s syndrome: report of two cases. Acta Haematol 1992; 88: 154–7PubMedCrossRef
138.
Sacchi S., Kantarjian H., O’Brien S., et al. Immune-mediated and unusual complications during alpha-interferon therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13: 2401–7PubMed
139.
Ely H. White blood cells as mediators of hyperviscosity-induced tissue damage in neutrophilic vascular reactions: therapy with pentoxifylline editorial]. J Am Acad Dermatol 1989; 20: 677–80PubMedCrossRef
140.
Ely H. Is pentoxifylline the drug of the decade? [editorial]. J Am Acad Dermatol 1994; 30: 639–42PubMedCrossRef
Metadata
Title
Sweet’s Syndrome
A Review of Current Treatment Options
Authors
Dr Philip R. Cohen
Razelle Kurzrock
Publication date
01-04-2002
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 2/2002
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200203020-00005

Other articles of this Issue 2/2002

American Journal of Clinical Dermatology 2/2002 Go to the issue

Therapy in Practice

Diagnosis and Management of Uncommon Cutaneous Cancers

Leading Article

Six Novel Antimycotics

Pharmacovigilance

Cutaneous Drug Reaction Case Reports

Therapy in Practice

Leishmaniasis

Review Article

Laser Hair Removal